Vandana Abramson
Faculty Member
Last active: 3/27/2014

  1. Stand up to cancer phase Ib study of pan-phosphoinositide-3-kinase inhibitor buparlisib with letrozole in estrogen receptor-positive/human epidermal growth factor receptor 2-negative metastatic breast cancer. Mayer IA, Abramson VG, Isakoff SJ, Forero A, Balko JM, Kuba MG, Sanders ME, Yap JT, Van den Abbeele AD, Li Y, Cantley LC, Winer E, Arteaga CL (2014) J Clin Oncol 32(12): 1202-9
    › Primary publication · 24663045 (PubMed) · PMC3986383 (PubMed Central)
  2. New strategies for triple-negative breast cancer--deciphering the heterogeneity. Mayer IA, Abramson VG, Lehmann BD, Pietenpol JA (2014) Clin Cancer Res 20(4): 782-90
    › Primary publication · 24536073 (PubMed) · PMC3962777 (PubMed Central)
  3. DCE-MRI analysis methods for predicting the response of breast cancer to neoadjuvant chemotherapy: pilot study findings. Li X, Arlinghaus LR, Ayers GD, Chakravarthy AB, Abramson RG, Abramson VG, Atuegwu N, Farley J, Mayer IA, Kelley MC, Meszoely IM, Means-Powell J, Grau AM, Sanders M, Bhave SR, Yankeelov TE (2014) Magn Reson Med 71(4): 1592-602
    › Primary publication · 23661583 (PubMed) · PMC3742614 (PubMed Central)
  4. Time course of arthralgia among women initiating aromatase inhibitor therapy and a postmenopausal comparison group in a prospective cohort. Castel LD, Hartmann KE, Mayer IA, Saville BR, Alvarez J, Boomershine CS, Abramson VG, Chakravarthy AB, Friedman DL, Cella DF (2013) Cancer 119(13): 2375-82
    › Primary publication · 23575918 (PubMed) · PMC3687009 (PubMed Central)
  5. Thrombotic microangiopathy during docetaxel, trastuzumab, and carboplatin chemotherapy for early-stage HER2+ breast cancer: a case report. Iams W, Beckermann KE, Neff AT, Mayer IA, Abramson VG (2013) Med Oncol 30(2): 568
    › Primary publication · 23564368 (PubMed) · PMC3774143 (PubMed Central)
  6. Parameterizing the Logistic Model of Tumor Growth by DW-MRI and DCE-MRI Data to Predict Treatment Response and Changes in Breast Cancer Cellularity during Neoadjuvant Chemotherapy. Atuegwu NC, Arlinghaus LR, Li X, Chakravarthy AB, Abramson VG, Sanders ME, Yankeelov TE (2013) Transl Oncol 6(3): 256-64
    › Primary publication · 23730404 (PubMed) · PMC3660793 (PubMed Central)
  7. Machine learning for predicting the response of breast cancer to neoadjuvant chemotherapy. Mani S, Chen Y, Li X, Arlinghaus L, Chakravarthy AB, Abramson V, Bhave SR, Levy MA, Xu H, Yankeelov TE (2013) J Am Med Inform Assoc 20(4): 688-95
    › Primary publication · 23616206 (PubMed) · PMC3721158 (PubMed Central)
  8. Early assessment of breast cancer response to neoadjuvant chemotherapy by semi-quantitative analysis of high-temporal resolution DCE-MRI: preliminary results. Abramson RG, Li X, Hoyt TL, Su PF, Arlinghaus LR, Wilson KJ, Abramson VG, Chakravarthy AB, Yankeelov TE (2013) Magn Reson Imaging 31(9): 1457-64
    › Primary publication · 23954320 (PubMed) · PMC3807825 (PubMed Central)
  9. Complications of targeted drug therapies for solid malignancies: manifestations and mechanisms. Abramson RG, Abramson VG, Chan E, Horn L, Keedy VL, Pao W, Sosman JA (2013) AJR Am J Roentgenol 200(3): 475-83
    › Primary publication · 23436834 (PubMed) · PMC3652983 (PubMed Central)
  10. Circulating neuregulin during the transition from stage A to stage B/C heart failure in a breast cancer cohort. Geisberg CA, Abdallah WM, da Silva M, Silverstein C, Smith HM, Abramson V, Mayer I, Means-Powell J, Freehardt D, White B, Lenihan D, Sawyer DB (2013) J Card Fail 19(1): 10-5
    › Primary publication · 23273589 (PubMed) · PMC3562720 (PubMed Central)